i-ED COIL

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. April 25, 2020 Kaneka Pharma America LLC % Takeaki Miyata Manager, Regulatory Affairs & Quality Assurance Team Kaneka Corporation 1-12-32 Akasaka Minato-ku, Tokyo 107-6028 Japan Re: K192068 Trade/Device Name: i-ED COIL System Regulation Number: 21 CFR 882.5950 Regulation Name: Neurovascular Embolization Device Regulatory Class: Class II Product Code: HCG, KRD Dated: March 25, 2020 Received: March 26, 2020 Dear Takeaki Miyata: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Xiaolin Zheng, Ph.D., M.S. Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ #### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration #### Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below. 510(k) Number (if known) K192068 Device Name i-ED COIL System #### Indications for Use (Describe) The i-ED COIL System (i-ED COIL and EDG v4) is intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The i-ED COIL System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and venous embolizations in the peripheral vasculature. | Type of Use (Select one or both, as applicable) | <table><tr><td><span> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span></td><td><span>☐ Over-The-Counter Use (21 CFR 801 Subpart C)</span></td></tr></table> | <span> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> | <span>☐ Over-The-Counter Use (21 CFR 801 Subpart C)</span> | |-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------| | <span> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> | <span>☐ Over-The-Counter Use (21 CFR 801 Subpart C)</span> | | | CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ***DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*** The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 510(K) SUMMARY ## i-ED COIL System #### 510(k) Submitter Kaneka Pharma America LLC 546 Fifth Avenue, 21st Floor, New York NY, The United States Contact Person: Kazuhiko Inoue Telephone: 212-705-4343 Email: Kazuhiko.inoue@kaneka.com #### Official Correspondent Takeaki Miyata Manager, Regulatory Affairs & Quality Assurance Team Medical Devices Solutions Vehicle Kaneka Corporation 1-12-32, Akasaka, Minato-ku Tokyo, Japan Phone: +81-3-5574-8023 Email: Takeaki.Miyata@kaneka.co.jp Date Prepared: April 25, 2020 {4}------------------------------------------------ ## Subject Device Name: | Trade Name | i-ED COIL System | |----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------| | Common or usual name | Neurovascular Embolization Device and<br>Vascular Embolization Device | | Classification name | Neurovascular Embolization Device [21 CFR<br>882.5950; product code HCG] and Vascular<br>Embolization Device [21 CFR 870.3300;<br>product code KRD] | | Class | II | | Classification Panel | Neurology (84) and Cardiovascular (74) | #### Predicate Devices: - . Primary predicate device: Target Detachable Coils / InZone Detachment System (or Target Coils and InZone System) [K161429 / K160096 (Stryker Neurovascular)] - . MicroPlex Coil System [K162999 (MicroVention, Inc.)] - Barricade Embolization Coil System (or Barricade Coil System) [K151760 (Blockade Medical)] These predicate devices have not been subject to a design-related recall. ### Device Description: i-ED COIL System is a neurovascular and vascular embolization device, which consists of two component devices, i-ED COIL Detachable Coil (hereafter i-ED COIL) and ELECTRO DETACH GENERATOR v4 Detachment System (hereafter EDG v4). The i-ED COIL is composed of a detach coil and a sheath adapter. Furthermore, the detach coil consists of a platinum coil (embolization material), to be placed at the site of vascular diseases, a pusher (delivery wire) to guide the platinum coil to the site and a PVA (polyvinyl alcohol) rod that connects the platinum coil and the pusher. The sheath adapter consists of a PP (polypropylene) sheath and an adapter. The i-ED COIL is designed for use with the EDG v4. The EDG v4 consists of a power source and connection cables attached with clips. EDG v4 is a medical electrical equipment to be used to detach the implantable platinum coil from the delivery wire of the i-ED COIL. It is intended for use in multiple coil detachments performed during a single procedure. {5}------------------------------------------------ The i-ED COIL and EDG v4 are provided sterile (EtO), and separately packaged and distributed in the U.S. ### Indications for Use The i-ED COIL System (i-ED COIL and EDG v4) is intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The i-ED COIL System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolizations in the peripheral vasculature. #### Comparison of Indications for Use to Predicate Devices The i-ED COIL System has the same intended use (vascular and neurovascular embolization and permanent occlusion of blood flow) as the Target Coils and InZone System, MicroPlex Coil System and Barricade Coil System. The indications for use of the i-ED COIL System is identical to those of the MicroPlex Coil System and the Barricade Coil System, and similar to that of the Target Coils and InZone System. #### Comparison of Technological Characteristics to Predicate Device Catheter-based vascular and neurovascular intervention is the technological principle for both i-ED COIL System and the predicate devices. The vascular and neurovascular embolization coil devices including the i-ED COIL System and the predicate devices consist of a coil (embolization material) and a delivery wire and an instrument for detachment of a coil (detachment system device). Comparison table of the technological characteristics to the primary predicate device is provided in Table 1 below: | Characteristics | Primary Predicate Device | Subject Device | Identicalness<br>/ similarity,<br>or difference | |-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------| | | Target Coils and InZone<br>System) [K161429 / K160096<br>(Stryker Neurovascular)] | i-ED COIL System (Kaneka<br>Corporation) | | | General Information | | | | | Intended use | Vascular and neurovascular<br>embolization and permanent<br>occlusion of blood flow. | Vascular and neurovascular<br>embolization and permanent<br>occlusion of blood flow. | Identical | | Configuration of an<br>embolization coil<br>device | The Target Coils consists of an<br>embolization coil implant<br>comprised of platinum-tungsten<br>alloy, affixed to a delivery wire<br>with an introducer sheath to | The i-ED COIL consists of an<br>embolization coil implant<br>comprised of platinum-tungsten<br>alloy, affixed to a pusher<br>(delivery wire) with a sheath | Similar | | | Primary Predicate Device | Subject Device | Identicalness<br>/ similarity, or difference | | Characteristics | Target Coils and InZone System) [K161429 / K160096<br>(Stryker Neurovascular)]<br>facilitate insertion into the hub<br>of a microcatheter. | i-ED COIL System (Kaneka Corporation)<br>adapter to facilitate insertion<br>into the hub of a microcatheter. | Identical | | Usage environments | Hospital, interventional<br>neuroradiology sites | Hospital, interventional<br>neuroradiology sites | Identical | | | Dimension/Shepe of Coil | | | | Primary coil outer<br>diameter (mm) | 0.25 to 0.43 | • Helical: 0.25 to 0.43<br>• Complex: 0.25 to 0.35 | Similar | | Secondary coil outer<br>diameter (mm) | 1.0 to 24.0 | • Helical: 1.5 to 24.0<br>• Complex: 1.0 to 16.0 | Similar | | Primary coil length<br>(mm) | • Helical: 10 to 500<br>• Complex: 11 to 500 | 10 to 500 | Similar | | Deployed coil shape | Helical, Complex (360 shape,<br>3D) | Helical, Complex | Similar | | Pusher length (mm) | 1850 | 1870 | Similar | | Pusher outer diameter<br>(grip part; mm) | 0.34 | 0.335 | Similar | | | Dimension of Detachment device | | | | Dimension (mm) | 140 × 58 × 28 | 125 × 55 × 25 | Similar | | | Material of Coil | | | | Coil | Platinum-tungsten alloy | Platinum-tungsten alloy | Identical | | Inner line (stretch<br>resistance) | Polypropylene suture (two<br>lines) | Polypropylene internal line<br>(two lines) | Identical | | Pusher (main or core<br>wire component) | Stainless steel | Stainless steel | Identical | | Sheath | High density polyethylene with<br>pigment | Polypropylene | Similar as<br>thermoplastic<br>resin | | | Specification of Detachment Device | | | | Coil detachment<br>principle | Electrolytic dissolution of<br>stainless steel | Thermal fusing of PVA rod | Different | | Circuit system | • Bi-polar type (for Target)<br>• Mono-polar type (for GDC<br>and Matrix) | Mono-polar type | Similar to for<br>detachment for<br>GDC and<br>Matrix | | Power source | Two AAAA (1.5 V) batteries | Three AA(1.5V) alkaline<br>batteries | Similar | | Output<br>current/voltage | Direct current (DC) up to 2.4<br>mA/ Volage up to 28 VDC | Alternate current (AC) up to 61.0<br>mA/ Voltage up to 22.5 V | Different | | Detachments per unit | 20 | 30 (based on the verification<br>test result) | Similar | | Other Characteristics | | | | | Radiopaque marker of<br>pusher | Yes | Yes (Platinum coil part of<br>pusher) | Similar | | Characteristics | Primary Predicate Device | Subject Device | Identicalness / similarity, or difference | | Concomitantly used devices | Microcatheter, guiding catheter, rotating hemostatic valve (RHV) | Microcatheter, guiding catheter, rotating hemostatic valve (RHV) | Identical | | Compatible microcatheter of coil (inner diameter: mm) | 0.41 to 0.48 | 0.33 to 0.53 (depending on dimensional specification of a platinum coil) | i-ED COIL has broader compatibility with microcatheter | | MRI compatibility of coil (stated in the IFU/DFU) | MR conditional | MR conditional | Similar (detailed conditions are different) | | Sterilization method | EtO | EtO | Identical | Table 1 Comparison table about technological characteristics {6}------------------------------------------------ {7}------------------------------------------------ ### Performance Testing To demonstrate substantial equivalence of i-ED COIL System to the predicate devices, the technological characteristics and performance criteria were evaluated in reference to the bench testing recommendations outlined in the FDA Guidance Document "Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices" (dated December 29, 2004). In vitro tests in Table 2 below were performed on the subject device: | Test | Test Method Summary | Results | |----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Appearance test on i-ED COIL | The purpose was to demonstrate that visual appearance of i-ED COIL meets pre-specified acceptance criteria and could be considered to be clinically usable.<br>Visual inspection using a microscope was conducted on the detach coil and the sheath adaptor. In addition, the position markers was visually checked. | All samples had no visual abnormalities at all and passed the acceptance criteria. | | Dimensional verification on i-ED COIL | The purpose was to demonstrate that dimensional values of i-ED COIL samples meet pre-specified acceptance criteria and the i-ED COIL samples are dimensionally designed as intended.<br>Dimensions of the samples were measured with instruments (gauge, caliper, and scale). | All samples were confirmed to meet all acceptance criteria based on the dimensional specification. | | Strength test on i-ED COIL | The purpose was to demonstrate that physical strength of i-ED COIL meet pre-specified acceptance criteria, and could withstand forces that the i-ED COIL may encounter in clinical usage.<br>After swelling the PVA rod, inner line strength, product strengths, coil strength and pusher strength were measured by a tensile tester. | All samples without deviation passed each acceptance criterion. It was demonstrated that i-ED COIL has necessary strength for clinical usage. | | Delivery performance test on i-ED COIL | The purpose was to demonstrate that delivery performance of i-ED COIL is at least equivalent to the control device that is legally distributed in the U.S.<br>A test sample was inserted into the microcatheter in a simulated ICA circuit Consequently the test sample was | All samples met the acceptance criteria about maximum load based on the result of the control device | | Test | Test Method Summary | Results | | Detachment<br>performance test<br>on i-ED COIL<br>System | The purpose was to demonstrate that i-ED COIL could be<br>detachable with the EDG v4 within pre-specified time, and<br>the combination of i-ED COIL and the EDG v4 is a reliable<br>detachment mechanism for the clinical usage.<br>According to the IFU, after the PVA rod of the detach coil<br>was swelled, the detach coil was advanced through the<br>sheath adapter. The detachment part of the sample was<br>soaked in heparinized saline at 35°C in the beaker. The tester<br>pressed the detach button of the EDG v4, and confirmed that<br>the platinum coil could be successfully detached from the<br>pusher within pre-specified time. | All test samples could be<br>detached within the pre-<br>specified time and met<br>the acceptance criteria. | | Detachment<br>durability test on<br>EDG v4 | In order to demonstrate the detachment reliability of i-ED<br>COIL System and durability of the EDG v4, it was measured<br>whether sufficient power for the detachment of i-ED COIL<br>was output from the EDG v4 samples during 30 times<br>detachment operations using the digital power meter and<br>non-inductive variable resistor. | Since the outputs from<br>all EDG v4 samples<br>during 30 times<br>detachment procedures<br>were stable, the<br>acceptance criteria<br>was met. | | Corrosion<br>resistance test on<br>i-ED COIL | The purpose was to demonstrate that the i-ED COIL does not<br>show sign of corrosions in the intended clinical use.<br>In reference to ISO 11070: 2014, test procedures were<br>carried out. The tester confirmed whether there was sign of<br>corrosion in metal section of sample using a digital<br>microscope. | In all test samples, there<br>was no sign of corrosion.<br>Therefore, the result met<br>the acceptance criterion. | | Particulate<br>evaluation on i-<br>ED COIL | The purpose was to demonstrate that the quantity and size of<br>particulates generated during operation of i-ED COIL<br>System are equivalent or less than particulates generated<br>from the control device that is distributed in the U.S.<br>The simulated use test model incorporated with the tortuous<br>part was used for the evaluation. After 20 cycles of retraction<br>and advancement of a test sample were repeated in the<br>model, the platinum coil was detached with the EDG v4. The<br>test sample solution and the baseline sample solution were<br>analysed using the light obscuration tester. | The particulates<br>generated from i-ED<br>COIL were equivalent or<br>less than the control<br>device. Therefore, the<br>result met the acceptance<br>criterion. | | Simulated use<br>evaluation on i-<br>ED COIL<br>System | In order to simulate actual clinical environment, the vessel<br>model with aneurysms, the biplane imaging system and<br>simulated worst neurovascular system, guiding catheter,<br>microcatheters, etc. were used in this test. Physicians who<br>participated in this study, semi-quantitatively evaluated<br>trackability and delivery performance in microcatheter, coil<br>positioning performance, repositioning performance (repeat<br>delivery), framing, filling and finishing performance, and<br>detachment performance of i-ED COIL System. | Considering the test<br>results, the i-ED COIL<br>System was judged to be<br>able to use without<br>problems even in the<br>very tortuous<br>vasculature considered<br>to be the worst case. | | Usability<br>evaluation on i-<br>ED COIL<br>System | The purpose was to evaluate the usability of i-ED COIL<br>System by physician trained for neuro-interventional<br>procedures.<br>Prior to the testing, the physicians were briefed on the device<br>operation, testing procedures, and were provided i-ED COIL<br>and EDG v4 IFUs. The physicians semi-quantitatively | In all of stages, all of<br>physicians scored the<br>usability as equal to or<br>greater than the<br>acceptance criterion.<br>Therefore, it was | | Test | Test Method Summary | Results | | MRI<br>Compatibility<br>tests on i-ED<br>COIL | scored each stage (from the preparation of i-ED COIL and<br>EDG v4 to the detachment of the platinum coil).<br><br>In reference to related FDA Guidance 'Establishing Safety<br>and Compatibility of Passive Implants in the Magnetic<br>Resonance (MR) Environment' and related ASTM F2052-<br>15, ASTM F2213-06, ASTM F2182-11a, and ASTM<br>F2119-07, effects of dispalacement force, torque, heating by<br>RF fields, image artifact of MR imaging on implanted i-ED<br>COIL were evaluated to establish safety and compatibility of<br>i-ED COIL in the MR environment. | COIL System had<br>adequate usability.<br><br>It was concluded that i-ED COIL was MR<br>conditional as same as<br>the predicate devices.<br>The MR compatibility<br>information was<br>reflected appropriately<br>in the labeling. | | MRA Artifact on<br>i-ED COIL | According to ASTM F2119-07, image artifact of i-ED COIL<br>in MR Angiography was measured. | The worst-case image<br>artifact by i-ED COIL<br>was considered as<br>minimal as with the<br>predicate device. | | Shelf Life testing<br>on i-ED COIL | In order to establish shelf life of i-ED COIL, aging test was<br>conducted on samples that underwent simulated<br>transportation (according to ISO 4180) and accelerated-<br>aged storage equivalent to three years real time storage. The<br>test items were same as above-mentioned performance<br>testing except for the MRI compatibility and MRA artifact<br>testings. Furthermore, to verify maintenance of sterility for<br>sterilization packages of i-ED COIL within the proposed<br>shelf life, package integrity tests were carried out on the<br>samples in reference to ASTM standards including<br>F88/F88M and F2096. | All results of the aging<br>tests met the acceptance<br>criteria were the same as<br>those of the performance<br>testing.<br>Therefore, three-years<br>shelf-life of i-ED COIL<br>was established. | Table 2 Summary of performance testing {8}------------------------------------------------ {9}------------------------------------------------ The results from these tests demonstrate that the technological characteristics and performance criteria of the i-ED COIL System are adequate for the intended use of the device, and that the device can perform in a manner equivalent to devices currently distributed on the market with the same intended use. ### Biocompatibility: To demonstrate the biological safety of the body-contacting materials and substantial equivalence of the i-ED COIL to the predicate devices, the biocompatibility testing listed in Table 3 below was performed in accordance with "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"; Guidance for Industry and Food and Drug Administration Staff" (dated June 16, 2016): | <b>Test item / Tested<br/>component</b> | <b>Test Method Summary</b> | <b>Results</b> | |-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Chemical<br>Characterization by<br>analysis of extracted<br>substances / Platinum<br>coil | In reference to USP<661> and ISO 10993-18, the<br>test articles were extracted by one or more than<br>one vehicle(s). The extracted substances were<br>analyzed by multiple analysis including GC-MS,<br>LC-MS and IC. | Analysis results showed that<br>the platinum coil did not<br>leach definite toxic<br>substances. | | Test item / Tested<br>component | Test Method Summary | Results | | Cytotoxicity /<br>Platinum coil, Pusher<br>and Sheath adapter | In reference to ISO 10993-5, cytotoxicity on V79<br>cells was examined by a colony formation assay<br>using medium extract. | Not cytotoxic (the medium<br>extract from test article did<br>not inhibit colony formation<br>of V79 cells) | | Sensitization / Platinum<br>coil, Pusher and Sheath<br>adapter | In reference to ISO 10993-10, a skin sensitization<br>test in guinea pigs was conducted using extracts<br>of the platinum coil, Pusher or Sheath Adapter by<br>physiological saline and olive oil.<br>In reference to ISO 10993-10, a skin sensitization<br>test in guinea pigs was conducted using extracts<br>of the platinum coil by methanol. | No-skin sensitizing potency | | Intracutaneous<br>Reactivity / Platinum<br>coil, Pusher and Sheath<br>adapter | In reference to ISO 10993-10, the test and control<br>solutions were intracutaneously injected into<br>rabbits. The injection sites were macroscopically<br>observed immediately after injection, and at 24,<br>48 and 72 hours after injection. | Acceptable intracutaneous<br>reactivity | | Acute Systemic Toxicity<br>/ Platinum coil, Pusher<br>and Sheath adapter | In reference to ISO 10993-11, the test and control<br>solutions prepared by extractions with vehicles<br>were injected into mice. Observation of general<br>conditions, measurement of body weight and<br>necropsy were performed on the mice. | No acute systemic toxicity<br>(test solution did not contain<br>any substance having acute<br>systemic toxicity) | | Pyrogenicity (material<br>mediated) / Platinum<br>coil, Pusher and Sheath<br>adapter | Material mediated rabbit pyrogen test was<br>conducted according to ISO 10993-11 and USP<br><151>. The body temperature of the animals were<br>measured before and after injection<br>(multiple timepoints) of extract. | Non-pyrogenicity (none of<br>the animals showed a body<br>temperature rise of 0.5°C or<br>more) | | Genotoxicity / Platinum<br>coil | In reference to ISO 10993-3 and OECD<br>Guideline No. 471, bacterial reverse mutation test<br>was conducted by the preincubation method with<br>and without metabolic activation system (S9 mix)<br>using tester strains.<br>In reference to ISO 10993-3 and OECD<br>Guideline No. 473, an <i>in vitro</i> chromosomal<br>aberration test in CHL/IU cells. | Non-mutagenic (no<br>mutagenic activity<br>(negative))<br>Non-mutagenic (no<br>induction of<br>chromosomal aberrations) | | Intramuscular<br>Implantation / Platinum<br>coil | In reference to ISO ISO 10993-6, platinum coils<br>were implanted into paravertebral muscles of<br>rabbits for 4 weeks and 13 weeks. The<br>implantation sites were examined<br>macroscopically and histologically. | No properties injurious to<br>the paravertebral muscle of<br>rabbits | | Heamocompatibility /<br>Platinum coil, Pusher<br>and Sheath adapter | In reference to ASTM F756 and ISO 10993-4, a<br>hemolysis test using human blood was conducted<br>on both, the extract of the component obtained<br>with PBS (-) (indirect contact condition; for<br>Platinum coil, Pusher and Sheath adapter) and the<br>component itself (direct contact condition; for<br>Platinum coil and Pusher).<br>In reference to ISO 10993-4, thrombogenicity<br>(coagulation system: TAT and platelet: β-TG) of<br>the Pusher was evaluated.<br>Changes in complement factors (SC5b-9) after<br>exposure of human serum or plasma to the | Non-hemolytic property<br>It was judged the<br>thrombogenesis risk was<br>equivalent or lower to that<br>of legally-marketed devices.<br>The complement activation<br>by the platinum coil and the<br>pusher was within the | | Test item / Tested<br>component | Test Method Summary | Results | | | platinum coil or the pusher, <i>in vitro</i> , were<br>examined. | acceptable range as a<br>medical device. | | Chronic Systemic<br>Toxicity / Platinum coil | In reference to ISO 10993-11, the platinum coils<br>were implanted subcutaneously in the back of rats<br>for 26 weeks, and chronic systemic toxicity was<br>evaluated. | The platinum coil did not<br>cause any chronic systemic<br>toxicities. | | Carcinogenicity /<br>Platinum coil | In reference to ISO 10993-17, toxicological Risk<br>Assessment on extracted substances was<br>conducted. | Non-carcinogenic | Table 3 Summary of biocompatibility testing {10}------------------------------------------------ {11}------------------------------------------------ The results from these tests demonstrate that the i-ED COIL System is biocompatible for its intended use similar to the predicate devices. ### Electrical safety and electromagnetic compatibility (EMC): Electrical safety and EMC testing were conducted on the EDG v4, consisting of the power source and connection cables attached clips. The detachment system device complies with the IEC 60601-1 standard for the electrical safety and the IEC 60601-1-2 standard for the EMC. ### Software Verification and Validation Testing: Software verification and validation testing were conducted, and documentation was provided in this 510(k) submission as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." (dated May 11, 2005). ### Conclusions: The i-ED COIL System met all of the predetermined acceptance criteria for the design verification and validation as specified by applicable standards, guidances, test protocols and/or customer inputs. The i-ED COIL System is substantially equivalent to legally marketed predicate devices.